학술논문
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial
Document Type
Article
Author
Source
In: Diabetes, Obesity and Metabolism . (Diabetes, Obesity and Metabolism, April 2021, 23(4):1020-1029)
Subject
Language
English
ISSN
14631326
14628902
14628902